Candel Therapeutics Reports Q3 GAAP EPS of -$0.28, Exceeding Estimates
Candel Therapeutics (CADL) reported third-quarter GAAP earnings per share of -$0.28, which outperformed analyst expectations by $0.07. The company demonstrated a significant increase in its liquidity position, reporting cash and cash equivalents of $203.1 million as of September 30, 2026, up from $119.7 million at the end of 2025. Based on current operating plans, management expects this strengthened cash position to provide sufficient funding for operations through the second quarter of 2028. This financial update highlights a stabilized runway for the company's ongoing clinical and operational activities.
Tickers: $CADL